JAPAN POINT OF CARE DIAGNOSTICS MARKET REPORT - TABLE OF CONTENTS

1. INTRODUCTION
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY

• 3.1 Market Highlights

4. VOICE OF CUSTOMER

• 4.1 Product and Market Intelligence
• 4.2 Factors Considered in Purchase Decisions
  • 4.2.1. Features
  • 4.2.2. Compatibility
  • 4.2.3. Durability
  • 4.2.4. Efficiency of Solutions
  • 4.2.4. After-Sales Support
  • 4.2.5. Consideration of Regulations

5. MARKET DYNAMICS

• 5.1. Market Overview
• 5.2. Demand Supply Analysis
• 5.3. Import and Export Analysis
• 5.4. Value Chain Analysis
• 5.5. Porter’s Five Forces Analysis
• 5.6. PESTLE Analysis
• 5.7. Pricing Analysis
• 5.8. Market Dynamics
• 5.9 MARKET DRIVERS
  • 5.9.1 Growing Geriatric Population Drives Point-of-Care Diagnostics Market
• 5.10 MARKET RESTRAINTS
  • 5.10.1 Strict approval process for commercialization of products
• 5.11 MARKET OPPORTUNITY
  • 5.11.1 Increased Fundings Support the Growth of the Point-of-Care Diagnostics Market in Japan
• 5.12 PORTER'S FIVE FORCE ANALYSIS
  • 5.12.1 Bargaining Power of Buyers/Consumers
  • 5.12.2 Bargaining Power of Suppliers
  • 5.12.3 Threat of New Entrants
  • 5.12.4 Threat of Substitute Products
  • 5.12.5 Intensity of Competitive Rivalry

6. MARKET SEGMENTATION (Market Size by Value - USD 2025-2033)

• 6.1 By Product
  • 6.1.1. Glucose Monitoring
  • 6.1.1.1. Strips
  • 6.1.1.2. Meters
  • 6.1.1.3. Lancets
  • 6.1.2. Cardiometabolic Testing Products
  • 6.1.2.1. Cardiac Marker Testing Products
  • 6.1.2.1.1. High Sensitive Troponin-I (hsTnl)
  • 6.1.2.1.2. Brain natriuretic peptide (BNP)
  • 6.1.2.1.3. D-dimer
  • 6.1.2.1.4. Creatine Kinase-MB (CK-MB)
  • 6.1.2.1.5. Myoglobin
  • 6.1.2.1.6. Others
  • 6.1.2.2. Blood Gas/Electrolytes Testing Products
  • 6.1.2.3. HbA1C Testing Products
  • 6.1.3. Infectious Disease Testing Products
  • 6.1.3.1. Sexually Transmitted Disease (STD) Testing Products
  • 6.1.3.2. Healthcare-associated Infection (HAI) Testing Products
  • 6.1.3.3. Respiratory Infection Testing Products
  • 6.1.3.4. Tropical Disease Testing Products
  • 6.1.3.5. Others
  • 6.1.4. Coagulation Testing Products
  • 6.1.4.1. Prothrombin Time (PT) Testing Products
  • 6.1.4.2. Activated Clotting Time/Activated Partial Thromboplastin Clotting Time (ACT/APTT) Testing Products
  • 6.1.5. Pregnancy and Fertility Testing Products
  • 6.1.5.1. Pregnancy Testing Products
  • 6.1.5.2. Fertility Testing Products
  • 6.1.6. Tumor/Cancer Marker Testing Products
  • 6.1.7. Cholesterol Testing Products
  • 6.1.8. Hematology Testing Products
  • 6.1.9. Drug-of-abuse (DoA) Testing Products
  • 6.1.10. Fecal Occult Testing Products
  • 6.1.11 Urinalysis Testing Products
  • 6.1.12 Others
• 6.2 By Prescription
  • 6.2.1. OTC Testing
  • 6.2.2. Prescription-based Testing
• 6.3 By End-user
  • 6.3.1. Hospitals
  • 6.3.2. Diagnostic Centers
  • 6.3.3 Research Laboratories
  • 6.3.4. Home-care Settings
  • 6.3.5 Others
• 6.4 By Region
  • 6.4.1. North [Hokkaido and Tohoku]
  • 6.4.2. Central [Kanto and Chubu]
  • 6.4.3. South [Kansai, Chugoku, Shikoku, and Kyushu &Okinawa]

7. COMPETITIVE LANDSCAPE

• 7.1. Expansion and Acquisition Analysis
  • 7.1.1. Expansion
  • 7.1.2. Acquisitions
• 7.2. Partnerships/Collaborations/Agreements/Exhibitions

8 PATENT LANDSCAPE
9 CASE STUDIES
10. COMPANY PROFILES

• 10.1 Abbott Laboratories
• 10.2 Hoffmann-La Roche Ltd
• 10.3 Sekisui Medical Co., Ltd.
• 10.4 Cepheid Inc.
• 10.5 BioMérieux SA
• 10.6 TAUNS Laboratories, Inc.
• 10.7 Fujirebio Holdings, Inc
• 10.8 Nova Biomedical Corporation
• 10.9 Becton, Dickinson and Company
• 10.10 Qiagen N.V.

*List Not Exhaustive

11. MARKET OPPORTUNITIES AND FUTURE TRENDS
12. STRATEGIC RECOMMENDATIONS
13. ABOUT US AND DISCLAIMER